China's Ribo acquires tech to bolster RNAi ambitions
This article was originally published in Scrip
Executive Summary
In another sign that Chinese firms are hungry for advanced technology to boost their innovative potential, Suzhou Ribo Life Sciences has licensed Life Technologies' technology for the delivery of novel RNA interfering therapeutics.